Next Article in Journal
Patterns of Prescribing Hydroxyurea for Sickle Cell Disease Patients from a Central Hospital, Saudi Arabia
Previous Article in Journal
Silent T-Cell Receptor Cutaneous T-Cell Lymphoma Associated to a Clonal Plasma Cell Proliferation
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Hematology Reports
Volume 11
Issue 1
10.4081/hr.2019.7912
hematolrep-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Hematology Reports is published by MDPI from Volume 14 Issue 1 (2022). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with PAGEPress.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Case Report

Use of Catridecacog in a Patient with Severe Factor XIII Deficiency Undergoing Surgery

by
Gianluca Sottilotta
1,
Francesca Luise
1,
Vincenzo Oriana
1,
Angela Piromalli
1,
Rosa Santacroce
2 and
Alessandra Di Lelio
3,*
1
UOSD Microcitemie—Centro Emofilia—Servizio Emostasi e Trombosi, Grande Ospedale Metropolitano Bianchi-Melacrino-Morelli, 89124 Reggio Calabria, Italy
2
Servizio di Genetica Medica, Azienda Ospedaliero-Universitaria Ospedali Riuniti di Foggia, 71122 Foggia, Italy
3
Center for Outcomes Research and Clinical Epidemiology—CORESEARCH, Via Tiziano Vecellio 2, 65124 Pescara, Italy
*
Author to whom correspondence should be addressed.
Hematol. Rep. 2019, 11(1), 7912; https://doi.org/10.4081/hr.2019.7912
Submission received: 17 October 2018 / Revised: 10 January 2019 / Accepted: 17 January 2019 / Published: 19 February 2019

Abstract

Despite many articles regarding the antihemorrhagic treatment and prophylaxis, there is a lack of experience about how to best conduct major surgical procedures in patients with congenital factor XIII (FXIII) deficiency. Here we report a case of surgery (right inguinal hernia, complicated by heaviness and pain) performed in a patient with FXIII deficiency, receiving recombinant FXIII prophylaxis (Catridecacog 35 UI/kg every 28 ± 2 days). Our experience shows that Catridecacog can be used safely and effectively not only for continued prophylaxis but also in surgery and adds to the very limited body of evidence currently available on surgery in this bleeding disorder.
Keywords: recombinant FXIII; congenital FXIII deficiency; surgery recombinant FXIII; congenital FXIII deficiency; surgery

Share and Cite

MDPI and ACS Style

Sottilotta, G.; Luise, F.; Oriana, V.; Piromalli, A.; Santacroce, R.; Di Lelio, A. Use of Catridecacog in a Patient with Severe Factor XIII Deficiency Undergoing Surgery. Hematol. Rep. 2019, 11, 7912. https://doi.org/10.4081/hr.2019.7912

AMA Style

Sottilotta G, Luise F, Oriana V, Piromalli A, Santacroce R, Di Lelio A. Use of Catridecacog in a Patient with Severe Factor XIII Deficiency Undergoing Surgery. Hematology Reports. 2019; 11(1):7912. https://doi.org/10.4081/hr.2019.7912

Chicago/Turabian Style

Sottilotta, Gianluca, Francesca Luise, Vincenzo Oriana, Angela Piromalli, Rosa Santacroce, and Alessandra Di Lelio. 2019. "Use of Catridecacog in a Patient with Severe Factor XIII Deficiency Undergoing Surgery" Hematology Reports 11, no. 1: 7912. https://doi.org/10.4081/hr.2019.7912

Article Metrics

Back to TopTop